Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Asthma
Interventions
Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
Conditions
Asthma
Interventions
ipratropium
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 2 Interventional Results available

Revefenacin in Acute Respiratory Insufficiency in COPD

NCT04315558
Conditions
COPD, Acute Respiratory Failure
Interventions
Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
14
States / cities
Birmingham, Alabama • Downey, California • Los Angeles, California + 11 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Vibrating Mesh Nebulizer, Jet Nebulizer
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Bronchospasm, Exercise-Induced
Interventions
ipratropium bromide, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Conditions
Acute Lung Injury
Interventions
Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
Drug · Other · Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Clackamas, Oregon • Portland, Oregon
Conditions
Asthma
Interventions
Fluticasone with salmeterol, Fluticasone HFA, Ipratropium HFA, Albuterol HFA
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Hackensack, New Jersey • New York, New York
Conditions
Bronchial Asthma, Status Asthmaticus
Interventions
Standard of Care therapies, NiPPV Therapy, Routine Respiratory Care
Procedure · Device
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed Phase 3 Interventional Results available

Actuation Indicator Trial in Patients With COPD

NCT00928746
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Ipratropium bromide
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
7
States / cities
Lafayette, Louisiana • Easley, South Carolina • Gaffney, South Carolina + 3 more
Conditions
Asthma
Interventions
Nebulizer (breath-actuated versus conventional continuous-output)
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
1 Year to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Completed No phase listed Observational Results available

Pharmacogenetics of b2-Agonists in Asthma.

NCT00708227
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Completed Phase 2 Interventional Results available

Treating Respiratory Emergencies in Children Study

NCT06074185
Conditions
Asthma in Children
Interventions
Ipratropium Bromide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Charlotte, North Carolina • Salt Lake City, Utah
Conditions
Familial Dysautonomia
Interventions
Albuterol-sulphate, Ipratropium-bromide, placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
TV48108, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
20 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Medford, Oregon • Spartanburg, South Carolina
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Combivent (Ipratropium/Albuterol)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Budesonide, budesonide/formoterol, Ipratropium/albuterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
45 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • Torrance, California • Denver, Colorado + 4 more
Conditions
COPD
Interventions
Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
Combination Product
Lead sponsor
Pneuma Respiratory, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hickory, North Carolina
Conditions
Status Asthmaticus
Interventions
Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Not yet recruiting Phase 2 Interventional

Effect of Ipratropium Bromide on EILO

NCT07394036
Conditions
Exercise-Induced Laryngeal Obstruction, Dyspnea During Activity
Interventions
Ipratropium Bromide, Normal Saline (Placebo)
Drug
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
8 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Prosper, Texas
Conditions
Dyspnea, Tetraplegia
Interventions
ipratropium (Atrovent)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
The Bronx, New York